KARYOPHARM THERAPEUTICS INC's ticker is KPTI and the CUSIP is 48576U106. A total of 155 filers reported holding KARYOPHARM THERAPEUTICS INC in Q4 2022. The put-call ratio across all filers is 1.24 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $29,736 | -24.9% | 22,191 | +0.4% | 0.00% | – |
Q2 2023 | $39,572 | -40.2% | 22,107 | +29.9% | 0.00% | – |
Q1 2023 | $66,212 | +16.4% | 17,021 | +1.7% | 0.00% | – |
Q4 2022 | $56,882 | -31.5% | 16,730 | +10.7% | 0.00% | – |
Q3 2022 | $83,000 | +25.8% | 15,111 | +2.5% | 0.00% | – |
Q2 2022 | $66,000 | -58.2% | 14,744 | -30.8% | 0.00% | – |
Q1 2022 | $158,000 | -7.1% | 21,299 | -19.2% | 0.00% | – |
Q4 2021 | $170,000 | +14.9% | 26,371 | +4.0% | 0.00% | – |
Q3 2021 | $148,000 | -55.4% | 25,345 | -21.2% | 0.00% | -100.0% |
Q2 2021 | $332,000 | +7.8% | 32,172 | +9.9% | 0.00% | 0.0% |
Q1 2021 | $308,000 | -26.0% | 29,268 | +8.8% | 0.00% | -50.0% |
Q4 2020 | $416,000 | +39.6% | 26,889 | +31.6% | 0.00% | +100.0% |
Q3 2020 | $298,000 | -25.9% | 20,433 | -3.7% | 0.00% | -50.0% |
Q2 2020 | $402,000 | +72.5% | 21,220 | +75.0% | 0.00% | 0.0% |
Q1 2020 | $233,000 | -43.9% | 12,127 | -44.0% | 0.00% | 0.0% |
Q4 2019 | $415,000 | +83.6% | 21,664 | -7.6% | 0.00% | +100.0% |
Q3 2019 | $226,000 | +63.8% | 23,455 | +2.1% | 0.00% | 0.0% |
Q2 2019 | $138,000 | -9.2% | 22,962 | -11.7% | 0.00% | 0.0% |
Q1 2019 | $152,000 | -36.9% | 26,015 | +1.3% | 0.00% | -50.0% |
Q4 2018 | $241,000 | -53.8% | 25,675 | -16.2% | 0.00% | -50.0% |
Q3 2018 | $522,000 | -3.3% | 30,630 | -3.6% | 0.00% | 0.0% |
Q2 2018 | $540,000 | +46.7% | 31,759 | +15.7% | 0.00% | +100.0% |
Q1 2018 | $368,000 | +26.0% | 27,442 | -9.8% | 0.00% | 0.0% |
Q4 2017 | $292,000 | -7.9% | 30,437 | +5.4% | 0.00% | -33.3% |
Q3 2017 | $317,000 | +28.9% | 28,871 | +6.3% | 0.00% | +50.0% |
Q2 2017 | $246,000 | -23.8% | 27,154 | +8.0% | 0.00% | -33.3% |
Q1 2017 | $323,000 | +8.8% | 25,133 | -20.5% | 0.00% | 0.0% |
Q4 2016 | $297,000 | +21.7% | 31,601 | +26.2% | 0.00% | 0.0% |
Q3 2016 | $244,000 | +22.6% | 25,032 | -15.6% | 0.00% | 0.0% |
Q2 2016 | $199,000 | -23.8% | 29,655 | +1.3% | 0.00% | -25.0% |
Q1 2016 | $261,000 | -38.6% | 29,279 | -8.8% | 0.00% | -20.0% |
Q4 2015 | $425,000 | +37.1% | 32,097 | +9.0% | 0.01% | +25.0% |
Q3 2015 | $310,000 | -63.7% | 29,441 | -6.3% | 0.00% | -66.7% |
Q2 2015 | $855,000 | -11.6% | 31,434 | -0.5% | 0.01% | +9.1% |
Q1 2015 | $967,000 | +5.1% | 31,580 | +28.5% | 0.01% | 0.0% |
Q4 2014 | $920,000 | +227.4% | 24,569 | +307.2% | 0.01% | +175.0% |
Q2 2014 | $281,000 | +15.2% | 6,034 | -23.7% | 0.00% | +33.3% |
Q1 2014 | $244,000 | – | 7,913 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Delphi Management Partners VIII, L.L.C. | 2,263,006 | $13,170,000 | 9.51% |
Palo Alto Investors LP | 5,383,052 | $31,329,000 | 1.89% |
Birchview Capital, LP | 246,000 | $1,432,000 | 0.97% |
Rubric Capital Management LP | 3,375,758 | $19,647,000 | 0.55% |
Lombard Odier Asset Management (Switzerland) SA | 1,517,804 | $8,834,000 | 0.55% |
RICE HALL JAMES & ASSOCIATES, LLC | 1,401,861 | $8,159,000 | 0.30% |
AlphaCentric Advisors LLC | 136,000 | $792,000 | 0.20% |
Bridgefront Capital, LLC | 20,946 | $122,000 | 0.13% |
Hennion & Walsh Asset Management, Inc. | 407,474 | $2,371,000 | 0.12% |
Virtus ETF Advisers LLC | 44,364 | $258,000 | 0.11% |